Travis Dunckley

Arizona State University — United States

Medicine · Health Sciences

32h-index5.7kcitations63works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(26), RNA Research and Splicing(7), Amyotrophic Lateral Sclerosis Research(7), Down syndrome and intellectual disability research(7), Parkinson's Disease Mechanisms and Treatments(6)

Publications58 total

Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and Neuroinflammation
2026Open Access
Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B
Journal of Medicinal Chemistry·2024· 9 cited
A novel DYRK1a inhibitor, DYR533, reduces tau pathology and TNF alpha in the 3xTg‐AD and PS19 mouse models
Alzheimer s & Dementia·2023Open Access
DNA methylation changes associated with Parkinson’s disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood
Figshare·2023Open Access
DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity
Scientific Reports·2022· 13 citedOpen Access
The Omnipresence of DYRK1A in Human Diseases
International Journal of Molecular Sciences·2022· 58 citedOpen Access
DNA Methylation and Expression Profiles of Whole Blood in Parkinson’s Disease
Frontiers in Genetics·2021· 79 citedOpen Access
Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice
Molecular Neurobiology·2019· 40 cited
DNA methylation changes associated with Parkinson’s disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood
Epigenetics·2019· 87 citedOpen Access
DNA methylation changes associated with Parkinson’s disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood
Figshare·2019Open Access
Dyrk1 inhibition improves Alzheimer's disease‐like pathology
Aging Cell·2017· 123 citedOpen Access
The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer’s Disease
Journal of Alzheimer s Disease·2016· 15 citedOpen Access
Next-generation profiling to identify the molecular etiology of Parkinson dementia
Neurology Genetics·2016· 30 citedOpen Access
The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer’s Disease
Journal of Alzheimer s Disease·2016· 93 citedOpen Access
Epigenetics of Cognition and Neurodegenerative Disorders
Neuromethods·2014
Harmine treatment enhances short-term memory in old rats: Dissociation of cognition and the ability to perform the procedural requirements of maze testing
Physiology & Behavior·2014· 35 citedOpen Access
SMG1 Identified as a Regulator of Parkinson’s Disease-Associated alpha-Synuclein through siRNA Screening
PLoS ONE·2013· 17 citedOpen Access
Beyond Secretases
Annual reports in medicinal chemistry·2013· 5 cited
Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s?
ACS Chemical Neuroscience·2012· 137 cited
Corrigendum to “Association between GAB2 haplotype and higher glucose metabolism in Alzheimer's disease-affected brain regions in cognitively normal APOEε4 carriers” [NeuroImage 54/3 (2011) 1896–1902]
NeuroImage·2011· 2 cited
page 1 of 3Next →

Frequent Co-authors

Eric M. Reiman(17), Dietrich A. Stephan(15), Thomas G. Beach(12), Winnie S. Liang(11), Richard J. Caselli(11), Matthew J. Huentelman(9), Bessie Meechoovet(9), Andrew Grover(8), Joseph Rogers(8), Keith D. Coon(8), Christopher Hulme(8), Diego Mastroeni(7), Walter A. Kukull(6), Amanda Myers(6), David W. Craig(6), Jason J. Corneveaux(6), John C. Morris(5), John V. Pearson(5), Andreas Papassotiropoulos(5), Breland E. Smith(5)